CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
CORT$75.03+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Product revenue, net | $675,040 | $482,375 | $401,858 |
| Operating expenses: | |||
| Cost of sales | 10,882 | 6,481 | 5,385 |
| Research and development | 246,887 | 184,353 | 130,991 |
| Selling, general and administrative | 280,320 | 184,259 | 152,848 |
| Settlement expense related to Melucci litigation | — | — | 14,000 |
| Insurance recovery related to Melucci litigation | — | — | (14,000) |
| Total operating expenses | 538,089 | 375,093 | 289,224 |
| Income from operations | 136,951 | 107,282 | 112,634 |
| Interest and other income | 24,542 | 17,275 | 3,557 |
| Income before income taxes | 161,493 | 124,557 | 116,191 |
| Income tax expense | (20,284) | (18,417) | (14,773) |
| Net income | $141,209 | $106,140 | $101,418 |
| Net income attributable to common stockholders | $139,733 | $105,496 | $101,288 |
| Basic net income per common share | $1.35 | $1.02 | $0.95 |
| Diluted net income per common share | $1.23 | $0.94 | $0.87 |
| Weighted-average shares outstanding used in computing net income per common share | |||
| Basic | 103,232 | 103,560 | 106,787 |
| Diluted | 113,480 | 111,742 | 115,966 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.